Robbins Arroyo LLP: Lexicon Pharmaceuticals, Inc. (LXRX) Misled Shareholders According to a Recently Filed Class Action
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Business Wire
SAN DIEGO & THE WOODLANDS, Texas--(BUSINESS WIRE)-- Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between March 11, 2016 to January 17, 2019. Lexicon is a biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/lexicon-pharmaceuticals/ Lexicon Accused of Issuing Materially False Statements According to the complaint, Lexicon entered into a collaboration and license agreement with Sanofi for Sotagliflozin, also known as "Zynquista", in November 2015. For nearly three years since, Lexicon repeatedly touted the benefits of
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
LXRX
Earnings
- 5/2/24 - Miss
LXRX
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/29/24 - Form 4
- LXRX's page on the SEC website